Brunt Tibor M, van Genugten Marianne, Höner-Snoeken Kathrin, van de Velde Marco J, Niesink Raymond J M
From the *Drug Monitoring System, Netherlands Institute of Mental Health and Addiction, Utrecht; †Department of Psychiatry, University of Amsterdam, Amsterdam; ‡Department of Pharmacy, University of Utrecht, Utrecht; and §Office for Medicinal Cannabis, Ministry of Health, The Hague, The Netherlands.
J Clin Psychopharmacol. 2014 Jun;34(3):344-9. doi: 10.1097/JCP.0000000000000129.
In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special focus on their delta-9-tetrahydrocannabinol and cannabidiol content. In a cross-sectional and natural design, users of pharmaceutical-grade cannabis were investigated with questionnaires. Medical background of the patients was asked as well as experienced therapeutic effects and characteristics of cannabis use. Subjective effects were measured with psychometric scales and used to compare among the strains of cannabis used across this group of patients. One hundred two patients were included; their average age was 53 years and 76% used it for more than a year preceding this study. Chronic pain (53%; n = 54) was the most common medical indication for using cannabis followed by multiple sclerosis (23%; n = 23), and 86% (n = 88) of patients (almost) always experienced therapeutic satisfaction when using pharmaceutical cannabis. Dejection, anxiety, and appetite stimulation were found to differ among the 3 strains of cannabis. These results show that patients report therapeutic satisfaction with pharmaceutical cannabis, mainly pain alleviation. Some subjective effects were found to differ among the available strains of cannabis, which is discussed in relation to their different tetrahydrocannabinol/cannabidiol content. These results may aid in further research and critical appraisal for medicinally prescribed cannabis products.
在荷兰，药用级种植大麻由卫生部委托进行分发以用于医疗目的。到目前为止，很少有研究描述其在患者中的治疗效果或主观（不良）影响。本研究的目的是评估一组使用处方药用级大麻的患者的治疗满意度，并比较现有菌株之间的主观影响，特别关注其Δ-9-四氢大麻酚和大麻二酚含量。在一项横断面自然设计中，对药用级大麻使用者进行问卷调查。询问了患者的医学背景以及大麻使用的体验治疗效果和特征。用心理测量量表测量主观影响，并用于比较该组患者使用的大麻菌株。纳入了102名患者；他们的平均年龄为53岁，76%的患者在本研究之前使用该药物超过一年。慢性疼痛（53%；n = 54）是使用大麻最常见的医学指征，其次是多发性硬化症（23%；n = 23），86%（n = 88）的患者在使用药用大麻时（几乎）总是体验到治疗满意度。发现三种大麻菌株在沮丧、焦虑和食欲刺激方面存在差异。这些结果表明，患者报告对药用大麻有治疗满意度，主要是疼痛缓解。发现现有大麻菌株之间存在一些主观影响差异，并结合其不同的四氢大麻酚/大麻二酚含量进行了讨论。这些结果可能有助于对药用大麻产品的进一步研究和批判性评估。
